ImmuneBiotech Achieves Strategic Breakthrough in China’s “Medical Silicon Valley” with Launch of GutMagnific® and Early Commercial Traction

Shahram Lavasani, CEO of Immune Biotech, and Mme Yao, business representative affiliated with Boao Super Hospital in Hainan

Lund, Sweden – ImmuneBiotech has reached an important milestone in China with the launch of its precision probiotic GutMagnific® in Hainan Province. The product has been introduced in the Boao Lecheng International Medical Tourism Pilot Zone, often referred to as China’s “Medical Silicon Valley” – a unique platform for advanced healthcare innovation.

The launch enables commercial entry into one of the world’s fastest-growing probiotic markets. Initial deliveries have already been completed, demonstrating early market demand. At the same time, the company is initiating clinical collaborations in the region to further strengthen its scientific position.

With regulatory approval for import and use, as well as patents, trademark protection, and established infrastructure, ImmuneBiotech has already begun commercial sales and started scaling its operations in China.

ImmuneBiotech is one of SmiLe Venture Hub’s alumni companies.

For more information, please read the full press release here.

Advancing Swedish Innovation into Global Markets
GutMagnific®, developed by ImmuneBiotech, is a clinically validated, multi-strain precision probiotic designed to restore gut microbiome balance, strengthen the intestinal barrier, and modulate immune function.
Building on its successful commercialization in Sweden, including national availability through Apoteket AB and MEDS Apotek, GutMagnific® is now expanding across EU markets and has established initial commercial traction in the United States, forming a foundation for further expansion as part of the company’s international scale-up strategy.

About ImmuneBiotech
ImmuneBiotech Medical Sweden AB is a Swedish biotechnology company based in Lund, focused on developing microbiome-based health solutions. With over two decades of research in immunology and the gut microbiome, the company is advancing a new category of precision probiotics targeting systemic health.

For further information, please contact:
Shahram Lavasani, CEO
ImmuneBiotech Medical Sweden AB
s.lavasani@immunebiotech.com
+46 700 90 8946
www.ImmuneBiotech.com
Learn more and purchase GutMagnific® at:
www.GutMagnific.com